EASD 2025 15 - 19 September 2025

CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m² and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)

Are you a healthcare professional?